Cover Image
市場調查報告書

突發性肺纖維化:主要9個國家的市場預測 (2015∼2025年)

Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 346435
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
突發性肺纖維化:主要9個國家的市場預測 (2015∼2025年) Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025
出版日期: 2015年12月08日 內容資訊: 英文 38 Pages
簡介

所謂突發性肺纖維化 (IPF) ,定義為原因不明的慢性、進行性的線維性間質性肺病變。是突發性的疾病,不過,有各種煤煙的暴露和抽煙等,特定可能性高的因素。

本報告提供全球主要9個國家(美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度) 的突發性肺纖維化的發病情形相關分析、疾病概要和目前的患病人數、性別、各年代 (5歲區分) 的詳細情況、各地區/各民族趨勢、風險要素、疾病診斷與預後、主要的症狀和併發症、未來趨勢預測 (今後10年份) 的資訊彙整為您概述為以下內容。

目錄

  • 圖表
  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷方法
  • 各地區/各人種的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 患者數的定量化的方法
    • 追加的資料 (按照要求提供)
  • 突發性肺纖維化 (IPF) 的最大的患病人數
    • IPF的種類
    • GAP模式的分期判斷
    • IPF的併發症
    • IPF患者的換氣支援
  • 本文中的簡稱一覽
  • Black Swan的其他出版刊物
  • Black Swan Analysis的患者為基礎的聯網數據庫
  • 以患者為基礎的服務
  • 線上價格趨勢資料/平台
  • 參考文件
  • 附錄

圖表一覽

目錄
Product Code: IPFS0011215

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. The disease is idiopathic, although a number of possible causes have been identified, including exposure to various dusts and smoking. This report provides the current prevalent population for IPF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a breakdown of the course of the disease, progressive vs. stable, with the definite diagnosed IPF patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of IPF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for IPF include:

  • GORD
  • Cardiovascular Disease
  • Presence of clubbing
  • Air ventilation assistance

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global IPF market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of IPF and identify patient segments with high potential. This would include patients diagnosed with definite or probable IPF.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on IPF's prevalent population.
  • Identify sub-populations within IPF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of IPF patients.

Coverage

  • US
  • UK
  • FR
  • DE
  • IT
  • ES
  • JP
  • BR
  • IN

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors and Prevention
  • Diagnosis of the Disease
  • Variation by Geography/ Ethnicity
  • Disease Prognosis and Clinical Course
  • Key Co-Morbid Conditions / Features associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Idiopathic Pulmonary Fibrosis
    • Type of IPF
    • GAP Staging
    • Co-morbid Conditions in IPF
    • Air Ventilation Assistance in IPF Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables and Figures

  • GAP Index for IPF Staging
  • Gap Staging System
  • Prevalence of IPF, total (000s)
  • Prevalence of IPF, males (000s)
  • Prevalence of IPF, females (000s)
  • Type of IPF present in patients, total (000s)
  • Course of disease in definite IPF patients, total (000s)
  • GAP stages in patients with definite IPF, total (000s)
  • GORD in patients with IPF, total (000s)
  • Presence of clubbing in patients with IPF, total (000s)
  • Cardiovascular disease in patients with IPF, total (000s)
  • Supplemental oxygen use in patients with IPF, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of IPF by 5-yr age cohort, males (000s)
  • USA Prevalence of IPF by 5-yr age cohort, females (000s)
  • France Prevalence of IPF by 5-yr age cohort, males (000s)
  • France Prevalence of IPF by 5-yr age cohort, females (000s)
  • Germany Prevalence of IPF by 5-yr age cohort, males (000s)
  • Germany Prevalence of IPF by 5-yr age cohort, females (000s)
  • Italy Prevalence of IPF by 5-yr age cohort, males (000s)
  • Italy Prevalence of IPF by 5-yr age cohort, females (000s)
  • Spain Prevalence of IPF by 5-yr age cohort, males (000s)
  • Spain Prevalence of IPF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of IPF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of IPF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of IPF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of IPF by 5-yr age cohort, females (000s)
  • Japan Prevalence of IPF by 5-yr age cohort, males (000s)
  • Japan Prevalence of IPF by 5-yr age cohort, females (000s)
  • India Prevalence of IPF by 5-yr age cohort, males (000s)
  • India Prevalence of IPF by 5-yr age cohort, females (000s)
Back to Top